Literature DB >> 1464277

Oxcarbazepine does not affect the anticoagulant activity of warfarin.

G Krämer1, B Tettenborn, P Klosterskov Jensen, G P Menge, K D Stoll.   

Abstract

The possible interaction of the antiepileptic drug oxcarbazepine (OCBZ) on the anticoagulant effect of warfarin was investigated in 10 healthy male volunteers. After reaching steady-state conditions by repeated administration of warfarin, the prothrombin time (Quick value) was assessed before and after single (600 mg) and multiple dosing (450 mg twice daily in 1 week) of OCBZ. In 7 of the 10 volunteers with evaluable data, the prothrombin time was not significantly different (paired t test) from baseline either after single (p = 0.299) or repeated dosing (p = 0.333), indicating that OCBZ does not interact to any relevant extent with the hypothrombinemic effect of warfarin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1464277     DOI: 10.1111/j.1528-1157.1992.tb01772.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  14 in total

Review 1.  Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance.

Authors:  P Loiseau
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

Review 2.  Oxcarbazepine: an update of its efficacy in the management of epilepsy.

Authors:  K Wellington; K L Goa
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 3.  Pharmacokinetic interactions of the new antiepileptic drugs.

Authors:  B Rambeck; U Specht; P Wolf
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

Review 4.  Management of seizures following a stroke: what are the options?

Authors:  Ronit Gilad
Journal:  Drugs Aging       Date:  2012-07-01       Impact factor: 3.923

Review 5.  Oxcarbazepine: a review of its use in children with epilepsy.

Authors:  Lynne Bang; Karen Goa
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 6.  [Seizures and epilepsies after stroke].

Authors:  H M Hamer
Journal:  Nervenarzt       Date:  2009-04       Impact factor: 1.214

7.  Overview of the clinical pharmacokinetics of oxcarbazepine.

Authors:  Gérard Flesch
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

8.  A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients.

Authors:  P J McKee; J Blacklaw; G Forrest; R A Gillham; S M Walker; D Connelly; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

Review 9.  Place of newer antiepileptic drugs in the treatment of epilepsy.

Authors:  R Kälviäinen; T Keränen; P J Riekkinen
Journal:  Drugs       Date:  1993-12       Impact factor: 9.546

Review 10.  Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine.

Authors:  R D Elwes; C D Binnie
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.